Drug profile · INN
sulfaphenazole
SULFABID
sulfaphenazole (SULFABID) is a bacterial dihydropteroate synthase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — sulfaphenazole
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
sulfaphenazole (SULFABID) is a bacterial dihydropteroate synthase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial dihydropteroate synthase inhibitor
Primary target: Dihydropteroate synthase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is sulfaphenazole?
sulfaphenazole (SULFABID) is a bacterial dihydropteroate synthase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for sulfaphenazole?
SULFABID is a marketed brand name for sulfaphenazole. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of sulfaphenazole?
sulfaphenazole has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.